

Jordi Bruix

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7097626/jordi-bruix-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

303
papers

86,771
citations

107
h-index

294
g-index

355
ext. papers

98,628
ext. citations

8.1
avg. IF

8.4
L-index

#	Paper	IF	Citations
303	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 378-90	59.2	9089
302	Management of hepatocellular carcinoma: an update. <i>Hepatology</i> , 2011 , 53, 1020-2	11.2	6091
301	Management of hepatocellular carcinoma. <i>Hepatology</i> , 2005 , 42, 1208-36	11.2	4778
300	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012 , 56, 908-43	13.4	4465
299	Hepatocellular carcinoma. <i>Lancet, The</i> , 2003 , 362, 1907-17	40	3580
298	Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. <i>Journal of Hepatology</i> , 2001 , 35, 421-30	13.4	3558
297	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012 , 379, 1245-55	40	3423
296	Prognosis of hepatocellular carcinoma: the BCLC staging classification. <i>Seminars in Liver Disease</i> , 1999 , 19, 329-38	7.3	2729
295	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <i>Lancet, The</i> , 2002 , 359, 1734-9	40	2679
294	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018 , 391, 1301-1314	40	2402
293	Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. <i>Hepatology</i> , 2003 , 37, 429-42	11.2	2207
292	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 56-66	40	1888
291	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. <i>Hepatology</i> , 1999 , 30, 1434-40	11.2	1594
290	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 35-43	21.7	1490
289	Design and endpoints of clinical trials in hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 698-711	9.7	1360
288	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016 , 150, 835-53	13.3	1012
287	Gene expression in fixed tissues and outcome in hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 1995-2004	59.2	979

286	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Gut</i> , 2014 , 63, 844-55	19.2	953
285	Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. <i>Hepatology</i> , 1999 , 29, 62-7	11.2	864
284	Prognostic prediction and treatment strategy in hepatocellular carcinoma. <i>Hepatology</i> , 2002 , 35, 519-24	11.2	843
283	Molecular targeted therapies in hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 48, 1312-27	11.2	801
282	Current strategy for staging and treatment: the BCLC update and future prospects. <i>Seminars in Liver Disease</i> , 2010 , 30, 61-74	7.3	770
281	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007 , 46, 474-81	13.4	734
280	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008 , 47, 97-104	11.2	718
279	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016 , 65, 719-726	13.4	709
278	Novel advancements in the management of hepatocellular carcinoma in 2008. <i>Journal of Hepatology</i> , 2008 , 48 Suppl 1, S20-37	13.4	635
277	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. <i>Hepatology</i> , 2001 , 33, 1124-9	11.2	595
276	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012 , 57, 821-9	13.4	589
275	Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. <i>Lancet, The</i> , 1989 , 2, 1004-6	4.0	571
274	Pivotal role of mTOR signaling in hepatocellular carcinoma. <i>Gastroenterology</i> , 2008 , 135, 1972-83, 1983.e1-11	11.3	563
273	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007 , 45, 938-47	11.2	557
272	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1344-54	21.7	553
271	The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2004 , 10, S115-20	4.5	513
270	Focus on hepatocellular carcinoma. <i>Cancer Cell</i> , 2004 , 5, 215-9	24.3	472
269	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3509-16	2.2	468

268	Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. <i>Cancer Research</i> , 2008 , 68, 6779-88	10.1	463
267	Management of HCC. <i>Journal of Hepatology</i> , 2012 , 56 Suppl 1, S75-87	13.4	438
266	Angiogenesis in liver disease. <i>Journal of Hepatology</i> , 2009 , 50, 604-20	13.4	438
265	Chemoembolization for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, S179-88	13.3	434
264	Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2012 , 18, 2290-300	12.9	426
263	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016 , 64, 1090-1098	13.4	407
262	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. <i>Hepatology</i> , 1998 , 27, 1578-83	11.2	403
261	SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 559-66	2.2	374
260	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <i>Cancer</i> , 2009 , 115, 616-23	6.4	359
259	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 557-588	24.2	355
258	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012 , 56, 1330-5	13.4	354
257	Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2004 , 40, 1352-60	11.2	340
256	LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. <i>Hepatology</i> , 2015 , 61, 1056-65	11.2	333
255	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. <i>Hepatology</i> , 2003 , 38, 1034-1042	11.2	331
254	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. <i>Journal of Hepatology</i> , 2017 , 67, 999-1008	13.4	321
253	A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. <i>Gastroenterology</i> , 2006 , 131, 1758-67	13.3	319
252	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. <i>Gastroenterology</i> , 2013 , 144, 829-40	13.3	317
251	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 525-35	19.4	315

250	Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. <i>Gastroenterology</i> , 2011 , 140, 1501-12.e2	13.3	307
249	Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. <i>Hepatology</i> , 1998 , 27, 1572-7	11.2	302
248	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010 , 51, 1274-83	11.2	292
247	Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. <i>Hepatology</i> , 1984 , 4, 1200-5	11.2	260
246	Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. <i>Hepatology</i> , 1993 , 18, 1121-1126	11.2	246
245	Major achievements in hepatocellular carcinoma. <i>Lancet, The</i> , 2009 , 373, 614-6	40	244
244	Tumor necrosis factor primes hepatocytes for DNA replication in the rat. <i>Hepatology</i> , 1998 , 28, 1226-34	11.2	238
243	Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. <i>Hepatology</i> , 1992 , 16, 353-7	11.2	233
242	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. <i>Liver Transplantation</i> , 2004 , 10, 1294-300	4.5	229
241	Hepatocellular carcinoma (HCC): a global perspective. <i>Journal of Clinical Gastroenterology</i> , 2010 , 44, 239-45	3	218
240	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , 2018 , 19, 682-693	21.7	216
239	Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. <i>Hepatology</i> , 1984 , 4, 442-6	11.2	214
238	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010 , 51, 2020-9	11.2	209
237	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. <i>Hepatology</i> , 2015 , 61, 526-36	11.2	207
236	Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009 , 50, 791-8	11.2	207
235	Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. <i>Hepatology</i> , 1990 , 12, 753-60	11.2	202
234	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018 , 69, 353-358	13.4	200
233	Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. <i>Hepatology</i> , 2001 , 33, 1073-9	11.2	200

232	Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. <i>Gastroenterology</i> , 2009 , 136, 1618-28.e2	13.3	197
231	Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 203-217	24.2	196
230	Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. <i>Hepatology</i> , 1982 , 2, 757-62	11.2	196
229	Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. <i>Clinical Cancer Research</i> , 2012 , 18, 4997-5007	12.9	195
228	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. <i>Hepatology</i> , 2000 , 31, 54-8	11.2	192
227	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010 , 52, 550-9	13.4	190
226	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009 , 51, 725-33	13.4	182
225	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. <i>Gastroenterology</i> , 2011 , 140, 1618-28.e16	13.3	181
224	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013 , 49, 3412-9	7.5	178
223	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015 , 62, S144-56	13.4	175
222	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014 , 61, 318-24	13.4	172
221	Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. <i>Annals of Surgery</i> , 1996 , 223, 297-302	7.8	172
220	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <i>Hepatology</i> , 2013 , 58, 2023-31	11.2	162
219	Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. <i>Gastroenterology</i> , 1995 , 109, 917-22	13.3	160
218	Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. <i>Journal of Hepatology</i> , 1985 , 1, 125-39	13.4	160
217	Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. <i>European Journal of Radiology</i> , 2018 , 101, 72-81	4.7	140
216	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2010 , 10, 209	4.8	138
215	Non-invasive diagnosis of hepatocellular carcinoma \geq 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012 , 56, 1317-23	13.4	135

214	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004 , 40, 1047-52	11.2	130
213	Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. <i>Journal of Hepatology</i> , 1998 , 29, 173-83	13.4	128
212	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , 2021 ,	13.4	127
211	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. <i>Hepatology</i> , 2003 , 38, 1034-42	11.2	126
210	New aspects of diagnosis and therapy of hepatocellular carcinoma. <i>Oncogene</i> , 2006 , 25, 3848-56	9.2	125
209	Endoscopic Measurement of Variceal Pressure in Cirrhosis: Correlation With Portal Pressure and Variceal Hemorrhage. <i>Gastroenterology</i> , 1989 , 96, 873-880	13.3	125
208	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 89-98	7	123
207	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. <i>Gut</i> , 2012 , 61, 1481-7	19.2	121
206	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012 , 56, 103-8	13.4	114
205	Natural history of hepatocellular carcinoma in Spain. Five year experience in 249 cases. <i>Journal of Hepatology</i> , 1990 , 10, 311-7	13.4	111
204	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019 , 156, 1731-1741	13.3	110
203	Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. <i>Cancer Research</i> , 2003 , 63, 859-64	10.1	110
202	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011 , 55, 1325-31	13.4	108
201	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1997 , 27, 959-65	13.4	107
200	Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. <i>Hepatology</i> , 2000 , 32, 679-80	11.2	107
199	Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. <i>Hepatology</i> , 1985 , 5, 245-50	11.2	105
198	c-met mRNA overexpression in human hepatocellular carcinoma. <i>Hepatology</i> , 1994 , 19, 88-91	11.2	104
197	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019 , 68, 1065-1075	19.2	100

196	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015 , 275, 698-707	20.5	99
195	Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. <i>Gastroenterology</i> , 2011 , 140, 1990-9	13.3	95
194	Chemoembolization for intermediate HCC: is there proof of survival benefit?. <i>Journal of Hepatology</i> , 2012 , 56, 984-6	13.4	89
193	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012 , 56, 1080-1088	13.4	88
192	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology</i> , 2012 , 13, 750-1	21.7	86
191	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <i>Hepatology</i> , 2011 , 54, 2238-44	11.2	84
190	Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?. <i>European Radiology</i> , 2006 , 16, 2454-62	8	84
189	Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. <i>Seminars in Liver Disease</i> , 2014 , 34, 444-55	7.3	83
188	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 617-630	24.2	82
187	Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. <i>Journal of Hepatology</i> , 1995 , 22, 410-5	13.4	80
186	Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. <i>Liver Transplantation</i> , 2003 , 9, 700-2	4.5	79
185	Hepatitis B virus and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2003 , 39 Suppl 1, S59-63	13.4	79
184	Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. <i>Gastroenterology</i> , 2009 , 137, 26-9	13.3	77
183	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. <i>Hepatology</i> , 1994 , 20, 643-650	11.2	77
182	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016 , 63, 839-49	11.2	74
181	Prognostic prediction in patients with hepatocellular carcinoma. <i>Seminars in Liver Disease</i> , 2005 , 25, 171-80	7.9	71
180	Endoscopic measurement of variceal pressure in cirrhosis: Correlation with portal pressure and variceal hemorrhage. <i>Gastroenterology</i> , 1989 , 96, 873-880	13.3	71
179	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007 , 46, 645-54	13.4	67

178	Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. <i>Hepatology</i> , 2003 , 38, 1458-67	11.2	67
177	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 478-478	2.2	62
176	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013 , 59, 1271-7	13.4	60
175	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017 , 37, 109-118	7.3	59
174	Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. <i>Journal of Hepatology</i> , 1999 , 30, 1028-34	13.4	59
173	Treatment of hepatocellular carcinoma: is there an optimal strategy?. <i>Cancer Treatment Reviews</i> , 2003 , 29, 99-104	14.4	58
172	Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. <i>Oncotarget</i> , 2015 , 6, 2509-23	3.3	55
171	Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment?. <i>Journal of Hepatology</i> , 1993 , 17, 187-91	13.4	55
170	Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA154-LBA154	2.2	55
169	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016 , 34, 597-602	3.2	51
168	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2991-3001	2.2	51
167	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021 , 75, 960-974	13.4	49
166	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019 , 70, 874-884	13.4	44
165	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018 , 67, 612-622	11.2	44
164	Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1989 , 34, 1765-9	4	44
163	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019 , 19, 3176-3184	8.7	43
162	High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. <i>Hepatology</i> , 2001 , 34, 158-67	11.2	38
161	p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2003 , 38, 591-7	13.4	37

160	Early diagnosis and treatment of hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2000 , 14, 991-1008	2.5	37
159	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 412-412	2.2	36
158	Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 1986 , 6, 1244-7	11.2	35
157	Akt-mediated foxo1 inhibition is required for liver regeneration. <i>Hepatology</i> , 2016 , 63, 1660-74	11.2	34
156	Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. <i>Hpb</i> , 2015 , 17, 387-93 ⁸	3.8	33
155	Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. <i>Liver Transplantation</i> , 2004 , 10, 1391-7	4.5	33
154	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018 , 24, 369-379	4.5	32
153	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 16701-16717	3.3	32
152	Selection of candidates with HCC for transplantation in the MELD era. <i>Liver Transplantation</i> , 2004 , 10, S4-9	4.5	31
151	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 482-491	6.1	30
150	Treatment of hepatocellular carcinoma. <i>Digestive Diseases</i> , 2014 , 32, 554-63	3.2	29
149	Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice. <i>Hepatology</i> , 2015 , 61, 433-6	11.2	28
148	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules . <i>Journal of Hepatology</i> , 2015 , 62, 150-5	13.4	28
147	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014 , 32, 4006-4006	2.2	28
146	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010 , 42 Suppl 3, S242-8	3.3	27
145	Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. <i>Virology Journal</i> , 2006 , 3, 98	6.1	27
144	Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. <i>Journal of Clinical Ultrasound</i> , 2003 , 31, 119-28	1	27
143	Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. <i>Journal of Hepatology</i> , 1995 , 22, 616-22	13.4	27

142	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019 , 1, 17-29	10.3	26
141	A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. <i>Journal of Molecular Medicine</i> , 2013 , 91, 939-50	5.5	26
140	Hepatocellular carcinoma [Authors' reply]. <i>Lancet, The</i> , 2012 , 380, 470-471	40	26
139	Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. <i>Seminars in Liver Disease</i> , 2006 , 26, 248-53	7.3	26
138	Prognostic assessment and evaluation of the benefits of treatment. <i>Journal of Clinical Gastroenterology</i> , 2002 , 35, S138-42	3	26
137	nm23-H1 expression and disease recurrence after surgical resection of small hepatocellular carcinoma. <i>Gastroenterology</i> , 1994 , 107, 486-91	13.3	26
136	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37 Suppl 1, 136-139	7.9	25
135	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021 , 73 Suppl 1, 137-149	11.2	25
134	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020 , 86, 101993	14.4	24
133	Hepatocellular carcinoma in the setting of liver transplantation. <i>Liver Transplantation</i> , 2006 , 12, 1028-36	4.5	24
132	Diagnosis of Small HCC. <i>Gastroenterology</i> , 2005 , 129, 1364	13.3	24
131	Surgical resection and survival in Western patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1992 , 15, 350-5	13.4	24
130	Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF- β pathway. <i>Oncotarget</i> , 2016 , 7, 71309-71329	3.3	23
129	Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. <i>Hepato-Gastroenterology</i> , 2004 , 51, 536-40		23
128	Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. <i>Clinical Cancer Research</i> , 2004 , 10, 2150-7	12.9	22
127	Liver transplantation in hepatocellular carcinoma. <i>Transplant International</i> , 2005 , 18, 278-82	3	22
126	Prognosis of hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2002 , 49, 7-11		22
125	The current status of liver transplantation for primary hepatic malignancy. <i>Clinics in Liver Disease</i> , 2000 , 4, 591-605	4.6	21

124	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	21
123	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. <i>Cancer Research</i> , 2019 , 79, 5167-5180	10.1	19
122	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009 , 29 Suppl 1, 148-58	7.9	19
121	Nonsurgical treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2000 , 6, S11-5	4.5	19
120	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2000 , 33, 423-9	13.4	19
119	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. <i>Annals of Saudi Medicine</i> , 2012 , 32, 174-99	1.6	19
118	A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. <i>Annals of Surgery</i> , 2015 , 262, e30	7.8	18
117	Two decades of advances in hepatocellular carcinoma research. <i>Seminars in Liver Disease</i> , 2010 , 30, 1-2	7.3	18
116	Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. <i>Radiology</i> , 2004 , 230, 300-1; author reply 301-2	20.5	18
115	Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. <i>Hepatology</i> , 1989 , 10, 269-72	11.2	18
114	Applicability of adult-to-adult living donor liver transplantation. <i>Journal of Hepatology</i> , 2005 , 43, 104-9	13.4	17
113	Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 109S, S149-S153	5.1	16
112	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC program. <i>Journal of Hepatology</i> , 2011 , 54, 227-35	13.4	16
111	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1239-44	2.2	16
110	Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 533-7	4	16
109	Hepatocellular carcinoma and the art of prognostication. <i>Journal of Hepatology</i> , 2000 , 33, 1006-8	13.4	16
108	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2020 , 72, 1267-1282	11.2	15
107	Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3451-60	5.9	15

106	Ablation for hepatocellular carcinoma: Is there need to have a winning technique?. <i>Journal of Hepatology</i> , 2010 , 52, 310-2	13.4	15
105	Treatment strategies for hepatocellular carcinoma in cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2003 , 7, 401-11	3.3	15
104	Diarrhea as a presenting symptom of hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1990 , 35, 681-5	4	15
103	Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 10	19.4	14
102	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014 , 1, 181-188	4	14
101	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020 , 24, 719-737	4.6	14
100	Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018 , 32, 2345-2354	5.2	14
99	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica</i> , 2017 , 149, 61-71	1	13
98	Prognostic prediction in HCC: Did anybody expect it to be easy?. <i>Hepatology</i> , 2004 , 39, 551-552	11.2	13
97	Locoregional treatments for hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 1999 , 13, 611-22	2.5	13
96	East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009 , 6, 14-5		12
95	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007 , 37 Suppl 2, S230-7	5.1	12
94	Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. <i>Journal of Hepatology</i> , 2006 , 44, 8-10	13.4	12
93	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1923-36	4	12
92	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter. <i>Clinical Cancer Research</i> , 2013 , 19, 4290	12.9	11
91	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
90	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021 , 3, 100260	0.3	11
89	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020 , 30, 186-194	8	11

88	Lenvatinib: can a non-inferiority trial change clinical practice?. <i>Lancet, The</i> , 2018 , 391, 1123-1124	4.0	10
87	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules \geq 1 cm in cirrhosis. <i>Liver International</i> , 2019 , 39, 1281-1291	7.9	9
86	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020 , 12,	6.6	9
85	Systemic treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 921-35	2.5	9
84	Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4078-4078	2.2	9
83	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017 , 23, 2448-2452	5.6	9
82	Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. <i>Journal of Hepatology</i> , 2021 , 74, 1483-1488	13.4	9
81	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021 , 135, 109484	4.7	9
80	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020 , 40, 1467-1476	7.9	8
79	Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. <i>Annals of Surgery</i> , 2015 , 261, e105	7.8	8
78	Sunitinib and the benefits of a negative study. <i>Lancet Oncology, The</i> , 2009 , 10, 743-4	21.7	8
77	Reply:. <i>Hepatology</i> , 2008 , 47, 2146-2147	11.2	8
76	Esophageal dysfunction in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1988 , 7, 362-7	13.4	8
75	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020 , 52, 1041-1046	3.3	7
74	Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. <i>Journal of Hepatology</i> , 2013 , 58, 452-9	13.4	7
73	Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. <i>Journal of Oncology Practice</i> , 2011 , 7, 155-60	3.1	7
72	Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 233-233	2.2	7
71	Intermediate-stage HCC--upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12,	19.4	6

70	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016 , 65, 864-865	13.4	6
69	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020 , 1866, 165687	6.9	5
68	The size of the problem: clinical algorithms. <i>Digestive Diseases</i> , 2013 , 31, 95-103	3.2	5
67	Expected developments in hepatology. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2002 , 16, 957-70	2.5	5
66	Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4159-TPS4159	2.2	5
65	Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. <i>Oncotarget</i> , 2017 , 8, 90185-90196	3.3	5
64	c-met mRNA overexpression in human hepatocellular carcinoma 1994 , 19, 88		5
63	Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients. <i>Hepatic Oncology</i> , 2016 , 3, 187-189	4	4
62	Sorafenib for hepatocellular carcinoma: global validation. <i>Gastroenterology</i> , 2009 , 137, 1171-3	13.3	4
61	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , 2022 , 11, 75-84	9.1	4
60	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020 , 30, 6694-6701	8	3
59	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014 , 61, 164-5	13.4	3
58	Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 197-197	2.2	3
57	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021 , 75, 1154-1163	13.4	3
56	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules \geq cm in cirrhotic patients. <i>European Radiology</i> , 2021 , 31, 4794-4803	8	3
55	Locoregional versus systemic therapy - robust positive data remain elusive. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 537-538	19.4	3
54	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021 , 27, 1767-1778	4.5	3
53	Reply. <i>Hepatology</i> , 2016 , 63, 1054-5	11.2	2

52	Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 1197-9	2.4	2
51	Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. <i>Virus Research</i> , 2017 , 240, 35-46	6.4	2
50	Diagnosis of early hepatocellular carcinoma: ideal goal, but not yet there. <i>Gastroenterology</i> , 2011 , 140, 358-60	13.3	2
49	Screening for liver cancer: the rush to judgment. <i>Annals of Internal Medicine</i> , 2012 , 157, 300-1; author reply 301-2	8	2
48	To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer?. <i>Gastroenterology</i> , 2009 , 137, 375-6; discussion 377	13.3	2
47	ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS498-TPS498	2.2	2
46	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials 1994 , 20, 643		2
45	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021 , 55, 263-270	3	2
44	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , 2021 , 156, 463.e1-463.e30	1	2
43	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021 , 12, 555	9.8	2
42	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	2
41	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , 2015 , 33, 590-7	3.2	1
40	Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma. <i>Hepatology</i> , 2018 , 68, 2042-2044	11.2	1
39	The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma. <i>Hepatology International</i> , 2014 , 8, 4-6	8.8	1
38	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , 2017 , 149, 61-71	0.3	1
37	Authors' Response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. <i>Gut</i> , 2015 , 64, 522	19.2	1
36	Hepatocellular carcinoma: paving the road for further developments. <i>Seminars in Liver Disease</i> , 2014 , 34, 361	7.3	1
35	The search for an effective partner for sorafenib: the failure of doxorubicin. <i>Gastroenterology</i> , 2011 , 140, 1687-8	13.3	1

34	Failure of interferon to prevent disease progression and liver cancer in hepatitis C virus infection: proof of absence or absence of proof?. <i>Gastroenterology</i> , 2010 , 138, 777-9	13.3	1
33	MicroRNA analysis for outcome prediction in hepatitis B virus-related liver cancer. <i>Gastroenterology</i> , 2010 , 138, 1624-6; discussion 1626-7	13.3	1
32	Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010 , 17, 420-1	2.8	1
31	Reply: Chemoembolization with drug eluting beads in HCC. <i>Journal of Hepatology</i> , 2007 , 47, 159	13.4	1
30	Ecografía con contraste de segunda generación (SonoVue®) en la valoración del tratamiento percutáneo del carcinoma hepatocelular. Comparación con la TC multifásica. <i>Radiología</i> , 2005 , 47, 79-85	0.6	1
29	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2021 ,	13.4	1
28	Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously". <i>Journal of Hepatology</i> , 2021 ,	13.4	1
27	Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS4163-TPS4163	2.2	1
26	Reply to: "The reported clear cut time association between interferon-free treatment and HCCOs anything but clear cut". <i>Journal of Hepatology</i> , 2020 , 72, 1036-1037	13.4	1
25	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020 , 40, 2476-2488	7.9	1
24	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021 , 9, 655-661	5.3	1
23	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , 2021 , 13, 5523-5533	3.6	1
22	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016 , 146, 511.e1-511.e22	0.3	1
21	Malignant Tumours1437-1463		1
20	The need for novel and interesting data in liver cancer research. <i>Hepatology</i> , 2009 , 50, 1690-1	11.2	0
19	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 428-428	2.2	0
18	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021 , 12, 440-449	3.3	0
17	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 463.e1-463.e30	0.3	0

16	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , 2019 , 71, 447-448	13.4
15	Reply to: Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis! <i>Journal of Hepatology</i> , 2015 , 62, 1453-4	13.4
14	Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2018 , 68, 620-621	13.4
13	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients 2014 , 77-93	
12	: a journal for all stakeholders in liver cancer management. <i>Hepatic Oncology</i> , 2014 , 1, 1	4
11	Reply: To PMID 25212123. <i>Hepatology</i> , 2015 , 62, 978-9	11.2
10	Reply:. <i>Hepatology</i> , 2009 , 50, 1316-1317	11.2
9	Transarterial Embolization for Patients with Hepatocellular Carcinoma 139-150	
8	Reply:. <i>Hepatology</i> , 2010 , 52, 1516-1517	11.2
7	Interferon for the prevention of hepatocellular carcinoma. <i>Perspectives in Medical Virology</i> , 2002 , 6, 151-159	
6	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterology & Hepatology</i> , 2022 ,	0.9
5	RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4156-TPS4156	2.2
4	Tumors of the Liver 773-785	
3	Letter: are sorafenib-related adverse events associated with prolonged survival? Authors Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 192	6.1
2	Reply to: "Correspondence on the".. <i>Journal of Hepatology</i> , 2022 ,	13.4
1	Management of Hepatocellular Cancer 740-754	